肠促胰岛素类制剂及二肽基肽酶抑制物的研究与临床应用进展
被引量：2
摘要
近年来我国的疾病谱发生了重大变化,包括糖尿病在内的慢性非传染性疾病严重影响了人民群众的健康。
2型糖尿病的治疗除了传统的磺脲类药物、双胍类药物及噻啶烷二酮类药物等外,出现了许多新型药物。下面就药物治疗新进展综述如下。
出处
《现代实用医学》
2009年第12期1276-1279,共4页
Modern Practical Medicine
同被引文献35
-
1Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes [J]. Diabetes Care, 2003, 26(10): 2929-2940.
-
2Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes [J]. Diabetologia, 1986, 29(1): 46-52.
-
3Nielsen LL, Young AA, Parkes DG. Pharmacology ofexenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes [J]. Regul Pept, 2004, 117(2): 77-88.
-
4Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus [J]. Am Health Syst Pharm, 2005, 62(2): 173-181.
-
5Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes [J]. J Clin Endocrinal Metab, 2003, 88(7): 3082-3089.
-
6Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years [J]. Curr Med Res Opin, 2008, 24(1): 275-286.
-
7Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study [J]. Clin Ther, 2008, 30(8): 1448-1460.
-
8Best JH, Hoogwerf B J, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifeline database [J]. Diabetes Care, 2011, 34(1): 90-95.
-
9Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes [J]. Diabetes Metab Res Rev, 2004, 20(5): 411-417.
-
10Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus [J]. Expert Opin lnvestig Drugs, 2007, 16(2): 231-237.
二级引证文献3
-
1宋滇平,杨晶晶,严巍.DPP-4抑制剂在特殊人群中应用宜与忌[J].药品评价,2011,8(21):38-41.
-
2吴敏,刘芳,付平.胰高血糖素样肽1与糖尿病肾病[J].中华肾脏病杂志,2011,27(12):941-944. 被引量：10
-
3李晴.概述糖尿病的治疗[J].上海医药,2014,35(8):45-47. 被引量：2
-
1成建国.常用抗心律失常药物的临床应用[J].西藏医药,2008,29(3):21-24.
-
2李晔蕾.抗心律失常药物治疗新进展[J].中国医学创新,2013,10(31):159-161. 被引量：7
-
3邱建清,纪洪新,张文静.难治性肺结核的药物治疗新进展[J].中国综合临床,1998,14(5):392-393. 被引量：1
-
4黄佳.血脂异常的药物治疗新进展[J].广西医学,1997,19(6):1029-1032.
-
5杨丽珍,余邦良.过敏性鼻炎药物治疗新进展[J].药学与临床研究,2013,21(5):543-546. 被引量：22
-
6邱建清,纪洪新,张文静.难治性肺结核的药物治疗新进展[J].临床肺科杂志,1998,3(1):1-3.
-
7金振波,孙文辉.癫痫病药物治疗新进展[J].中国新药杂志,2005,14(5):544-547. 被引量：9
-
8徐成斌.血脂异常的药物治疗新进展[J].中华心血管病杂志,2001,29(3):189-192. 被引量：84
-
9耿令奎,付燕.急性冠状动脉综合征的药物治疗新进展[J].医学综述,2005,11(7):660-661.
-
10陈顺科.Ⅱ型糖尿病吧药物治疗新进展[J].中国伤残医学,2012,20(3):124-125. 被引量：1
